Convergence starts study of drug for pain

Tuesday 19 July 2011

A recently created spin-out of GlaxoSmithKline Plc has started a Phase 2 study of a new small-molecule treatment for pain that acts against a sodium channel known as Nav1.7. The company is Convergence Pharmaceuticals Ltd.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom